Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
基本信息
- 批准号:10462786
- 负责人:
- 金额:$ 26.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-05 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:ATR geneAcuteAdenosine Diphosphate RiboseAlkylating AgentsAlkylating Antineoplastic AgentsAncillary StudyApoptosisAwardBase Excision RepairsBiological AssayBiological MarkersCHEK1 geneCancer HospitalCancer Therapy Evaluation ProgramCell LineCellsClinicClinicalClinical ResearchClinical TrialsClinical Trials DesignCollaborationsColorectal CancerCritical PathwaysDNA DamageDNA RepairDNA Repair PathwayDNA replication forkDataDevelopmentDiseaseDisease ProgressionDreamsEnrollmentEpigenetic ProcessFacultyFutile CyclingFutureGamma-H2AXGenomicsGliomaGoalsGrantGranzymeHealthHeterogeneityHypermethylationImmuneImmune TargetingImmune responseImmune systemImmunofluorescence ImmunologicImmunologic MarkersImmunologyImmunotherapyIn VitroIndividualInfiltrationInnovative TherapyInstructionLesionLifeMGMT geneMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMeasuresMedical OncologistMentorsMentorshipMethodsMismatch RepairMutationNational Cancer InstituteOncologyPathogenesisPathway interactionsPatient AgentsPatient-Focused OutcomesPatientsPatternPhase Ib/II Clinical TrialPhosphorylationPhysiciansPlayPoly(ADP-ribose) PolymerasesPolymerasePolypsPrevalencePrognostic MarkerPropertyPublic HealthResearch PersonnelResistanceRoleSamplingScientistSiteSpecimenT-LymphocyteTechniquesTestingTherapeuticThymineTissue MicroarrayTrainingTranslatingTumor-infiltrating immune cellsWorkXenograft procedureanticancer researchbasebiomarker identificationbiomarker-drivencancer typeclinical trial implementationcolon cancer cell linecolorectal cancer progressioncolorectal cancer treatmentdesignearly phase clinical trialexperienceexperimental studyimmunogenicityimmunoregulationimprovedin vivoinhibitorinnovationinvestigator-initiated trialmultidisciplinaryneoantigensnew therapeutic targetnext generationnovelnovel markernovel therapeutic interventionnovel therapeuticspre-clinicalpredictive markerpromoterrepairedreplication stressresponseskillstargeted treatmenttemozolomidetherapeutic targettooltumortumor heterogeneitytumor immunologytumor microenvironmenttumor-immune system interactionsvirtual
项目摘要
ABSTRACT
DNA repair plays an important role in the pathogenesis of virtually all cancer types, and the identification of
aberrant DNA repair pathways has identified predictive and prognostic biomarkers to targeted therapies. For
example, epigenetic hypermethylation of the promoter of O6-methylguanine DNA methyltransferase (MGMT)
predicts for better patient survival and increased sensitivity to temozolomide (TMZ) in multiple cancers,
including colorectal cancer (CRC). TMZ is a monofunctional alkylator, and the DNA damage caused by TMZ is
principally repaired by MGMT, which is silenced by promoter hypermethylation. The base excision repair (BER)
pathway also serves as a critical pathway to repair TMZ DNA damage. Preclinically, the simultaneous inhibition
of BER with polyp ADP ribose polymerase (PARP) inhibitors further sensitizes MGMT deficient tumors to TMZ.
However, our preliminary findings reveal an alternative and parallel mechanism: TMZ damage causes acute
replication stress and fork collapse leading to Ataxia Telangiectasia and Rad3 related (ATR) dependent
phosphorylation of Checkpoint Kinase 1 (Chk1). We have leveraged these findings, and additional in vivo
experiments, to advance novel TMZ combinations into the clinic with two investigator-initiated clinical trials for
MGMT silenced CRC: 1) TMZ + olaparib (PARP inhibitor) and TMZ + AZD 6738 (ATR inhibitor). Enrollment will
proceed at Yale Smilow Cancer Hospital with future opportunities expand to collaborating sites through our
CRC Stand up to Cancer (SU2C) Dream Team. Furthermore, we aim to develop new biomarker assays
including a biomarker assessing MGMT heterogeneity to identify tumors most sensitive to TMZ combinations,
and perform genomic profiling. Leveraging DNA damage additionally represents a potential tool to stimulate an
immune response, and through ancillary studies and using specimens obtained from our trials we will study the
effects TMZ combinations on the immune microenvironment to lend support to the addition of immunotherapy
in the future. I am a medical oncologist focusing on the treatment of advanced gastrointestinal (GI) cancers
with an emphasis on innovative therapies for CRC. This award will facilitate my development as a physician-
scientist equipped to design and conduct investigator-initiated early phase clinical trials based on innovative
preclinical evidence regarding DNA repair and immunotherapies. My training will include didactic coursework
for tumor immunology, practical experience of clinical trial implementation, and formal instruction in biomarker
techniques. To achieve these goals, I have assembled a multidisciplinary mentorship team led by my primary
mentor, Dr. Patricia LoRusso who has a proven track record of successfully mentoring junior faculty and
extensive expertise in investigator-initiated clinical trials. At the conclusion of this award, I will have gained
valuable skills into the underpinnings of clinical research generically, and specifically for clinical trial design,
and biomarker identification for DNA repair and immunology. This award will help establish me as an
independent investigator conducting early phase clinical trials for CRC and other GI cancers.
摘要
DNA修复在几乎所有癌症类型的发病机制中发挥着重要作用,并识别
异常DNA修复通路已经确定了靶向治疗的预测性和预后生物标志物。为
例如,O6-甲基鸟嘌呤DNA甲基转移酶(MGMT)启动子的表观遗传超甲基化
预测多种癌症的患者存活率更高,对替莫唑胺(TMZ)的敏感性增加,
包括结直肠癌(CRC)。TMZ是一种单功能烷化剂,TMZ对DNA的损伤是
主要由MGMT修复,而MGMT由启动子超甲基化沉默。碱基切除修复(BER)
途径也是修复TMZ DNA损伤的关键途径。临床前,同时抑制
息肉ADP核糖聚合酶(PARP)抑制剂的BER进一步增加MGMT缺陷肿瘤对TMZ的敏感性。
然而,我们的初步发现揭示了另一种平行的机制:TMZ损伤导致急性
复制应激和叉状塌陷导致共济失调毛细血管扩张症和Rad3相关(ATR)依赖
检查点激酶1(Chk1)的磷酸化。我们利用了这些发现,并在体内进行了额外的
实验,通过两项由研究人员发起的临床试验,将新的TMZ组合推向临床
MGMT使CRC沉默:1)TMZ+olaparib(PARP抑制剂)和TMZ+AZD 6738(ATR抑制剂)。注册将
在耶鲁·斯米洛癌症医院继续前进,未来有机会通过我们的
华润抗癌(SU2C)梦之队。此外,我们的目标是开发新的生物标志物分析方法。
包括评估MGMT异质性的生物标记物,以确定对TMZ联合最敏感的肿瘤,
并进行基因组图谱分析。利用DNA损伤还代表了一种潜在的工具,可以刺激
免疫反应,并通过辅助研究和使用从我们的试验获得的样本,我们将研究
TMZ联合用药对免疫微环境的影响为增加免疫治疗提供支持
在未来。我是一名内科肿瘤学家,专注于晚期胃肠道(GI)癌症的治疗
重点是结直肠癌的创新疗法。这个奖项将促进我作为一名医生的发展-
有能力设计和实施由研究人员发起的早期临床试验的科学家
有关DNA修复和免疫疗法的临床前证据。我的训练将包括授课课程
肿瘤免疫学,临床试验实施的实践经验,生物标记物的正式指导
技巧。为了实现这些目标,我组建了一个由我的主要负责人领导的多学科指导团队
导师,Patricia LoRusso博士,她有成功指导初级教员和
在研究人员发起的临床试验方面拥有丰富的专业知识。在这个奖项结束时,我将获得
临床研究基础的宝贵技能,特别是临床试验设计,
以及DNA修复和免疫学的生物标记物识别。这个奖项将有助于确立我作为一名
为结直肠癌和其他胃肠道癌症进行早期临床试验的独立调查者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Cecchini其他文献
Michael Cecchini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Cecchini', 18)}}的其他基金
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
- 批准号:
10675088 - 财政年份:2021
- 资助金额:
$ 26.1万 - 项目类别:
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
- 批准号:
10301255 - 财政年份:2021
- 资助金额:
$ 26.1万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 26.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 26.1万 - 项目类别:
Standard Grant